Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 45

1.

THE BENEFIT OF SHORT-TERM WEIGHT LOSS WITH ANTI-OBESITY MEDICATIONS IN REAL-WORLD CLINICAL PRACTICE.

Shibuya K, Ali KF, Ji X, Milinoivh A, Bauman J, Kattan MW, Pantalone KM, Burguera B.

Endocr Pract. 2019 Jun 26. doi: 10.4158/EP-2019-0081. [Epub ahead of print]

PMID:
31241358
2.

Testosterone replacement therapy and the risk of adverse cardiovascular outcomes and mortality.

Pantalone KM, George J, Ji X, Kattan MW, Milinovich A, Bauman JM, Burguera B, Zimmerman RS, Misra-Hebert AD.

Basic Clin Androl. 2019 Mar 29;29:5. doi: 10.1186/s12610-019-0085-7. eCollection 2019.

3.

Pericardial diseases in patients with hypothyroidism.

Chahine J, Ala CK, Gentry JL, Pantalone KM, Klein AL.

Heart. 2019 Jul;105(13):1027-1033. doi: 10.1136/heartjnl-2018-314528. Epub 2019 Apr 4. Review.

PMID:
30948517
4.

Relative contribution of basal and postprandial hyperglycaemia stratified by HbA1c categories before and after treatment intensification with dulaglutide.

Umpierrez G, Pantalone KM, Atisso CM, Landó LF, Patel H.

Diabetes Obes Metab. 2019 Jun;21(6):1365-1372. doi: 10.1111/dom.13662. Epub 2019 Mar 18.

PMID:
30756511
5.

VIRTUAL SHARED MEDICAL APPOINTMENTS: A NOVEL TOOL TO TREAT OBESITY.

Shibuya K, Pantalone KM, Burguera B.

Endocr Pract. 2018 Dec;24(12):1108-1109. doi: 10.4158/1934-2403-24.12.1108. No abstract available.

PMID:
30715909
6.

Intensification patterns and the probability of HbA1c goal attainment in Type 2 diabetes mellitus: real-world evidence for the concept of 'intensification inertia'.

Pantalone KM, Misra-Hebert AD, Hobbs TM, Ji X, Kong SX, Milinovich A, Weng W, Bauman JM, Ganguly R, Burguera B, Kattan MW, Zimmerman RS.

Diabet Med. 2019 Jan 17. doi: 10.1111/dme.13900. [Epub ahead of print]

PMID:
30653705
7.

Predicting Current Glycated Hemoglobin Values in Adults: Development of an Algorithm From the Electronic Health Record.

Wells BJ, Lenoir KM, Diaz-Garelli JF, Futrell W, Lockerman E, Pantalone KM, Kattan MW.

JMIR Med Inform. 2018 Oct 22;6(4):e10780. doi: 10.2196/10780.

8.

Obesity: Are shared medical appointments part of the answer?

Shibuya K, Pantalone KM, Burguera B.

Cleve Clin J Med. 2018 Sep;85(9):699-706. doi: 10.3949/ccjm.85a.18006. Review.

9.

TSH-STAINING PITUITARY ADENOMAS: RARE, SILENT, AND PLURIHOROMONAL.

Polanco Santos C, Sandouk Z, Yogi-Morren D, Prayson R, Recinos P, Kennedy L, Hamrahian AH, Pantalone KM.

Endocr Pract. 2018 Jun;24(6):580-588. doi: 10.4158/EP-2018-0084.

PMID:
29949434
10.

Clinical Inertia in Type 2 Diabetes Management: Evidence From a Large, Real-World Data Set.

Pantalone KM, Misra-Hebert AD, Hobbs TM, Ji X, Kong SX, Milinovich A, Weng W, Bauman J, Ganguly R, Burguera B, Kattan MW, Zimmerman RS.

Diabetes Care. 2018 Jul;41(7):e113-e114. doi: 10.2337/dc18-0116. Epub 2018 Apr 20. No abstract available.

PMID:
29678811
11.

Antidiabetic treatment patterns and specialty care utilization among patients with type 2 diabetes and cardiovascular disease.

Pantalone KM, Misra-Hebert AD, Hobbs TM, Ji X, Kong SX, Milinovich A, Weng W, Bauman J, Ganguly R, Burguera B, Kattan MW, Zimmerman RS.

Cardiovasc Diabetol. 2018 Apr 10;17(1):54. doi: 10.1186/s12933-018-0699-7.

12.

Patient Characteristics Associated With Severe Hypoglycemia in a Type 2 Diabetes Cohort in a Large, Integrated Health Care System From 2006 to 2015.

Misra-Hebert AD, Pantalone KM, Ji X, Milinovich A, Dey T, Chagin KM, Bauman JM, Kattan MW, Zimmerman RS.

Diabetes Care. 2018 Jun;41(6):1164-1171. doi: 10.2337/dc17-1834. Epub 2018 Mar 16.

PMID:
29549082
13.

Dulaglutide 1.5 mg as an add-on option for patients uncontrolled on insulin: Subgroup analysis by age, duration of diabetes and baseline glycated haemoglobin concentration.

Pantalone KM, Patel H, Yu M, Fernández Landó L.

Diabetes Obes Metab. 2018 Jun;20(6):1461-1469. doi: 10.1111/dom.13252. Epub 2018 Mar 23.

14.

Prevalence and recognition of obesity and its associated comorbidities: cross-sectional analysis of electronic health record data from a large US integrated health system.

Pantalone KM, Hobbs TM, Chagin KM, Kong SX, Wells BJ, Kattan MW, Bouchard J, Sakurada B, Milinovich A, Weng W, Bauman J, Misra-Hebert AD, Zimmerman RS, Burguera B.

BMJ Open. 2017 Nov 16;7(11):e017583. doi: 10.1136/bmjopen-2017-017583.

15.

Effect of glycemic control on the Diabetes Complications Severity Index score and development of complications in people with newly diagnosed type 2 diabetes.

Pantalone KM, Misra-Hebert AD, Hobbs TM, Wells BJ, Kong SX, Chagin K, Dey T, Milinovich A, Weng W, Bauman JM, Burguera B, Zimmerman RS, Kattan MW.

J Diabetes. 2018 Mar;10(3):192-199. doi: 10.1111/1753-0407.12613. Epub 2017 Nov 27.

PMID:
28976724
16.

AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY PROTOCOL FOR STANDARDIZED PRODUCTION OF CLINICAL PRACTICE GUIDELINES, ALGORITHMS, AND CHECKLISTS - 2017 UPDATE.

Mechanick JI, Pessah-Pollack R, Camacho P, Correa R, Figaro MK, Garber JR, Jasim S, Pantalone KM, Trence D, Upala S.

Endocr Pract. 2017 Aug;23(8):1006-1021. doi: 10.4158/EP171866.GL.

PMID:
28786720
17.

Association of glucagon-like peptide-1 receptor agonist use and rates of acute myocardial infarction, stroke and overall mortality in patients with type 2 diabetes mellitus in a large integrated health system.

Zimmerman RS, Hobbs TM, Wells BJ, Kong SX, Kattan MW, Bouchard J, Chagin KM, Yu C, Sakurada B, Milinovich A, Weng W, Bauman JM, Pantalone KM.

Diabetes Obes Metab. 2017 Nov;19(11):1555-1561. doi: 10.1111/dom.12969. Epub 2017 Jul 5.

PMID:
28407414
18.

Intensification of Diabetes Therapy and Time Until A1C Goal Attainment Among Patients With Newly Diagnosed Type 2 Diabetes Who Fail Metformin Monotherapy Within a Large Integrated Health System.

Pantalone KM, Wells BJ, Chagin KM, Ejzykowicz F, Yu C, Milinovich A, Bauman JM, Kattan MW, Rajpathak S, Zimmerman RS.

Diabetes Care. 2016 Sep;39(9):1527-34. doi: 10.2337/dc16-0227. Epub 2016 Aug 12.

PMID:
27519447
19.

Changes in Characteristics and Treatment Patterns of Patients with Newly Diagnosed Type 2 Diabetes in a Large United States Integrated Health System between 2008 and 2013.

Pantalone KM, Hobbs TM, Wells BJ, Kong SX, Kattan MW, Bouchard J, Chagin KM, Yu C, Sakurada B, Milinovich A, Weng W, Bauman JM, Zimmerman RS.

Clin Med Insights Endocrinol Diabetes. 2016 Jun 30;9:23-30. doi: 10.4137/CMED.S39761. eCollection 2016.

20.

Not All Diabetes in Infants is Type 1: A Case Report.

Arce KM, Pantalone KM.

Diabetes Ther. 2016 Jun;7(2):369-75. doi: 10.1007/s13300-016-0171-1. Epub 2016 Apr 26.

21.

Relationship between weight change and glycaemic control in patients with type 2 diabetes receiving once-weekly dulaglutide treatment.

Umpierrez GE, Pantalone KM, Kwan AY, Zimmermann AG, Zhang N, Fernández Landó L.

Diabetes Obes Metab. 2016 Jun;18(6):615-22. doi: 10.1111/dom.12660. Epub 2016 Apr 13.

22.

Measurement of Serum Free Thyroxine Index May Provide Additional Case Detection Compared to Free Thyroxine in the Diagnosis of Central Hypothyroidism.

Pantalone KM, Hatipoglu B, Gupta MK, Kennedy L, Hamrahian AH.

Case Rep Endocrinol. 2015;2015:965191. doi: 10.1155/2015/965191. Epub 2015 Dec 8.

23.

Clinical characteristics, complications, comorbidities and treatment patterns among patients with type 2 diabetes mellitus in a large integrated health system.

Pantalone KM, Hobbs TM, Wells BJ, Kong SX, Kattan MW, Bouchard J, Yu C, Sakurada B, Milinovich A, Weng W, Bauman JM, Zimmerman RS.

BMJ Open Diabetes Res Care. 2015 Jul 22;3(1):e000093. doi: 10.1136/bmjdrc-2015-000093. eCollection 2015.

24.

In Reply: Diabetes therapy and cardiac risk.

Zimmerman RS, Pantalone KM.

Cleve Clin J Med. 2015 Mar;82(3):140-1. doi: 10.3949/ccjm.82c.03002. No abstract available.

25.

Risk of overall mortality and cardiovascular events in patients with type 2 diabetes on dual drug therapy including metformin: A large database study from the Cleveland Clinic.

Kannan S, Pantalone KM, Matsuda S, Wells BJ, Karafa M, Zimmerman RS.

J Diabetes. 2016 Mar;8(2):279-85. doi: 10.1111/1753-0407.12301. Epub 2015 Jun 29.

PMID:
25929426
26.

Diabetes, patient-centered medical homes, and accountable care organizations, oh my!

Pantalone KM.

J Am Osteopath Assoc. 2015 Apr;115(4 Suppl):eS3-4. doi: 10.7556/jaoa.2015.056. Review. No abstract available.

PMID:
25928462
27.

Does mortality risk vary among sulfonylureas?

Pantalone KM.

Lancet Diabetes Endocrinol. 2015 Jan;3(1):6-7. doi: 10.1016/S2213-8587(14)70217-7. Epub 2014 Oct 22. No abstract available.

PMID:
25466240
28.

Diabetes management: More than just cardiovascular risk?

Zimmerman RS, Pantalone KM.

Cleve Clin J Med. 2014 Nov;81(11):672-6. doi: 10.3949/ccjm.81a.14033. No abstract available.

PMID:
25368217
29.

The clinical utility of free thyroxine in oral levothyroxine absorption testing.

Sun GE, Pantalone KM, Faiman C, Gupta M, Olansky L, Hatipoglu B.

Endocr Pract. 2014 Sep;20(9):925-9. doi: 10.4158/EP13487.OR.

PMID:
25100364
30.

Hyponatremia and the Thyroid: Causality or Association?

Pantalone KM, Hatipoglu BA.

J Clin Med. 2014 Dec 26;4(1):32-6. doi: 10.3390/jcm4010032.

31.

Mody-3: novel HNF1A mutation and the utility of glucagon-like peptide (GLP)-1 receptor agonist therapy.

Docena MK, Faiman C, Stanley CM, Pantalone KM.

Endocr Pract. 2014 Feb;20(2):107-11. doi: 10.4158/EP13254.OR.

PMID:
24014008
32.

Liraglutide effective in the severely insulin-resistant patient with type 2 diabetes requiring U-500 insulin: a case report.

Pantalone KM, Faiman C.

Diabetes Technol Ther. 2013 Apr;15(4):342-3. doi: 10.1089/dia.2012.0328. Epub 2013 Feb 4.

PMID:
23379638
33.

Male hypogonadism: more than just a low testosterone.

Pantalone KM, Faiman C.

Cleve Clin J Med. 2012 Oct;79(10):717-25. doi: 10.3949/ccjm.79a.11174. Review.

PMID:
23027731
34.

Hypothyroidism as a cause of hyponatremia: fact or fiction?

Sun GE, Pantalone KM, Hatipoglu B.

Endocr Pract. 2012 Nov-Dec;18(6):894-7. doi: 10.4158/EP12130.OR.

PMID:
22982798
35.

Is chronic nipple piercing associated with hyperprolactinemia?

Sun GE, Pantalone KM, Gupta M, Kennedy L, Nasr C, Constantiner M, Hamrahian AH, Hatipoglu B.

Pituitary. 2013 Sep;16(3):351-3. doi: 10.1007/s11102-012-0431-7.

PMID:
22965248
36.

Increase in overall mortality risk in patients with type 2 diabetes receiving glipizide, glyburide or glimepiride monotherapy versus metformin: a retrospective analysis.

Pantalone KM, Kattan MW, Yu C, Wells BJ, Arrigain S, Jain A, Atreja A, Zimmerman RS.

Diabetes Obes Metab. 2012 Sep;14(9):803-9. doi: 10.1111/j.1463-1326.2012.01604.x. Epub 2012 Apr 29.

PMID:
22486923
37.

The risk of overall mortality in patients with Type 2 diabetes receiving different combinations of sulfonylureas and metformin: a retrospective analysis.

Pantalone KM, Kattan MW, Yu C, Wells BJ, Arrigain S, Nutter B, Jain A, Atreja A, Zimmerman RS.

Diabet Med. 2012 Aug;29(8):1029-35. doi: 10.1111/j.1464-5491.2012.03577.x.

PMID:
22248043
38.

Use of insulin detemir and insulin glargine during pregnancy: are the data convincing?

Pantalone KM, Faiman C, Olansky L.

Endocr Pract. 2011 Sep-Oct;17(5):830; author's reply 830-1. No abstract available.

PMID:
22081832
39.

Insulin glargine use during pregnancy.

Pantalone KM, Faiman C, Olansky L.

Endocr Pract. 2011 May-Jun;17(3):448-55. doi: 10.4158/EP11083.RA. Review.

PMID:
21613047
40.

Glargine vs. NPH insulin therapy in pregnancies complicated by diabetes: an observational cohort study--comment on Negrato et al.

Pantalone KM, Agarwal S, Faiman C.

Diabetes Res Clin Pract. 2011 Jul;93(1):e9-10; author reply e11. doi: 10.1016/j.diabres.2011.03.027. Epub 2011 Apr 19. No abstract available.

PMID:
21507497
41.

Approach to a low TSH level: patience is a virtue.

Pantalone KM, Nasr C.

Cleve Clin J Med. 2010 Nov;77(11):803-11. doi: 10.3949/ccjm.77a.10056. Review.

PMID:
21048053
42.

The risk of overall mortality in patients with type 2 diabetes receiving glipizide, glyburide, or glimepiride monotherapy: a retrospective analysis.

Pantalone KM, Kattan MW, Yu C, Wells BJ, Arrigain S, Jain A, Atreja A, Zimmerman RS.

Diabetes Care. 2010 Jun;33(6):1224-9. doi: 10.2337/dc10-0017. Epub 2010 Mar 9.

43.

Change in adrenal mass size as a predictor of a malignant tumor.

Pantalone KM, Gopan T, Remer EM, Faiman C, Ioachimescu AG, Levin HS, Siperstein A, Berber E, Shepardson LB, Bravo EL, Hamrahian AH.

Endocr Pract. 2010 Jul-Aug;16(4):577-87. doi: 10.4158/EP09351.OR.

PMID:
20150023
44.

The risk of developing coronary artery disease or congestive heart failure, and overall mortality, in type 2 diabetic patients receiving rosiglitazone, pioglitazone, metformin, or sulfonylureas: a retrospective analysis.

Pantalone KM, Kattan MW, Yu C, Wells BJ, Arrigain S, Jain A, Atreja A, Zimmerman RS.

Acta Diabetol. 2009 Jun;46(2):145-54. doi: 10.1007/s00592-008-0090-3. Epub 2009 Feb 5.

PMID:
19194648
45.

Failure to thrive.

Pantalone KM.

Clin Pediatr (Phila). 2008 May;47(4):404-5. doi: 10.1177/0009922807309637. No abstract available.

PMID:
18424565

Supplemental Content

Loading ...
Support Center